Navigation Links
Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Date:12/7/2010

hree serious adverse events that were considered drug related to the study treatment.

In addition, the company announced the presentation of its poster titled "The Histone Deacetylase (HDAC) Inhibitor PCI-24781 decreases pro-inflammatory cytokine secretion in vitro and in vivo and protects against endotoxemia in a sepsis model" at the American Society of Hematology in Orlando on Monday December 6, 2010. The poster by Balasubramanian et al focuses on the anti-inflammatory properties of our HDAC inhibitor, PCI-24781.  Through modulation of the NF-kB pathway, PCI-24781 potently inhibits the transcription and secretion of pro-inflammatory cytokines and other mediators produced by myeloid cells.  As a result, PCI-24781 is effective in treating inflammatory disorders, as demonstrated by the potent inhibition of LPS-induced endotoxemia in a mouse model of sepsis.

ASH Conference Call and Webcast Details:Date: Wednesday, December 8, 2010Time: 4:30 pm ETSlides used in Presentation: http://ir.pharmacyclics.com/events.cfm Listen via Internet: http://ir.pharmacyclics.com/events.cfmLive Participant Dial In (Toll Free): 877-407-8133 Live Participant Dial In (International): 201-689-8040 To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at www.pharmacyclics.com.

About this trialThe Phase IA is a multicenter study being conducted in collaboration with investigators at leading lymphoma centers including Stanford University, MD Anderson Cancer Center, the University of Chicago, the University of Vermont, Weill Medical College of Cornell University,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015  Cepheid (Nasdaq: ... a flexible and portable clinical molecular diagnostic system ... of Care market.  At just 9 inches tall, ... will run the same high quality PCR-based Xpert® ... enabling highly accurate clinical molecular diagnostic tests to ...
(Date:7/28/2015)... , July 20, 2015 ... addition of the "Global Post-traumatic Stress Disorder Therapeutics ... The global PTSD therapeutics market to grow at a ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:7/27/2015)... CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today ... financial results on Thursday, August 6, 2015, after the ... members of the management team will host a webcast ... general corporate update at 4:30 p.m. EDT (1:30 p.m. ... follows: Thursday, August 6 1:30 p.m. PDT/4:30 ...
Breaking Medicine Technology:World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... Nov. 8, 2010 EXTENSION, INC . announced today ... will make available for general release to the healthcare community ... offerings use Cisco IP devices and smartphones as end points ... smartphone devices will not only serve as communication end points ...
... NYSE: SNY ) announced today that it has ... ) requesting that Genzyme clarify its position on a number ... Sanofi-aventis, letter also notes that it is encouraged by ... parties but observes that sanofi-aventis has not been contacted by ...
Cached Medicine Technology:EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows 2EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows 3Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions 2Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions 3Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions 4Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions 5
(Date:7/28/2015)... ... July 28, 2015 , ... According to Kxan ... the cycle of addiction in lab mice. The study involving isradipine has garnered national ... prospect of helping their clients overcome drug and alcohol addictions. The study was conducted ...
(Date:7/28/2015)... ... ... Bipolar disorder is often associated with mood swings ranging from depressive lows ... World Health Organization (WHO) has reported that bipolar disorder affects about 60 million people ... United States has the highest lifetime rate of bipolar disorder at 4.4% affecting 14 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) (“the ... time to time and depending on market conditions, to repurchase shares of its ... will be made in open market or privately negotiated transactions in compliance with ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Fertility ... chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top ... by hundreds of her esteemed colleagues and peers in the metro area as one ...
(Date:7/28/2015)... ... 28, 2015 , ... The PULs Cardiac Test™ identifies asymptomatic ... many of whom are missed by conventional evaluation , A currently unmet ... sub-clinical disease, who are at risk of experiencing a coronary event, and for ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... say risks of long-term use still outweigh possible benefits ... therapy once seemed like a wonderful means to help ... and progesterone as their bodies began to produce decreased ... fend off heart disease, osteoporosis and cancer. , But ...
... ... Immigration Conference and Job Fair Series includes events in New York on ... The annual series is free and provides a unique and educational opportunity ... and residency program directors and coordinators, who manage medical training programs at ...
... , , OAKLAND, Calif., Aug. ... their subsidiaries (KFHP/H) reported today a combined total operating revenue of ... $10.1 billion in the second quarter of last year. Operating ... in the second quarter of last year. Net non-operating income ...
... , , , ... WPI ), a leading specialty pharmaceutical company, announced today that ... the United States is being voluntarily recalled from wholesalers and pharmacies. ... dates of February 2011 and were manufactured by Watson Laboratories, Inc. ...
... on heavier children may miss the target, study finds ... testing guidelines for children may have to be revised, ... an effective indicator of high cholesterol in kids. , ... revised cholesterol screening guidelines that recommended a cholesterol check ...
... consumption to six cancers , FRIDAY, Aug. 7 (HealthDay News) ... alcohol over the course of his life appears to raise ... kinds of cancer, a new crunching of quarter-century-old research data ... more men drink, the greater their risk for specific cancers. ...
Cached Medicine News:Health News:In U.S., No Comeback Seen for Hormone Therapy 2Health News:In U.S., No Comeback Seen for Hormone Therapy 3Health News:14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series Kicks-Off in New York City 2Health News:14th Annual J-1/H-1B Foreign Physician Immigration Conference and Job Fair Series Kicks-Off in New York City 3Health News:Kaiser Foundation Health Plan and Hospitals Report Second Quarter 2009 Financial Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report Second Quarter 2009 Financial Results 3Health News:Kaiser Foundation Health Plan and Hospitals Report Second Quarter 2009 Financial Results 4Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 3Health News:Cholesterol Screening Shouldn't Rely on Kids' Weight 2Health News:Drinking Moderately or More Ups Men's Cancer Risk 2Health News:Drinking Moderately or More Ups Men's Cancer Risk 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: